Black Diamond rises on licensing deal for tumor treatment
19/03/2025 11:33
** Shares of precision oncology firm Black Diamond Therapeutics BDTX.O rise 35.1% to $2.26 premarket ** BDTX and French drugmaker Servier say they have entered into a licensing agreement for BDTX-4933, a small molecule designed by Black Diamond ** BDTX will receive an upfront payment of $70 million and will be eligible to receive up to $710 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales ** Under the agreement, Servier will develop and commercialize BDTX-4933 for solid tumors including non-small cell lung cancer ** BDTX-4933 is currently in early-stage development ** Up to last close, BDTX has fallen 64.2% in the past 12 months (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))